Details

Autor(en) / Beteiligte

• Van der Paardt, Anne-Fleur Louise
• Akkerman, Onno W
• Gualano, Gina
• Palmieri, Fabrizio
• Davies Forsman, Lina
• Aleksa, Alena
• Tiberi, Simon
• de Lange, Wiel C M
• Bolhuis, Mathieu S
• Skrahina, Alena
• van Soolingen, Dick
• Kosterink, Jos G W
• Migliori, Giovanni Battista
• van der Werf, Tjip S
• Alffenaar, Jan-Willem C

Titel

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis

Ist Teil von

• The European respiratory journal, 2017-03, Vol.49 (3), p.1601612-1601612

Ort / Verlag

England: European Respiratory Society Journals Ltd

Erscheinungsjahr

2017

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are an emerging global threat. An estimated 3.3% of newly diagnosed TB patients and 20% of previously treated patients worldwide have MDR-TB [1]. Moreover, 9.7% of MDR-TB cases are suffering from XDR-TB. Treatment of TB is becoming more difficult since the resistance pattern of Mycobacterium tuberculosis is expanding and treatment success rate is decreasing, with newly emerging drug-resistant strains [2]. Therefore, evaluation of antimicrobial drugs active against M. tuberculosis is necessary. Clarithromycin (CLR) is a macrolide antibiotic previously listed as a World Health Organization (WHO) group 5 drug, but not included in the new WHO classification because it has only modest bacteriostatic effects against M. tuberculosis [3]. However, the in vitro synergy of CLR in combination with linezolid, ethambutol and spectinomycin, and its immunomodulatory effects, hold promise [4–6]. Despite the introduction of newer drugs such as bedaquiline and delamanid, clarithromycin may have added value for the treatment of TB patients in cases of extensive resistance but proven susceptibility to clarithromycin. Unfortunately, real-life data on the use of clarithromycin to guide physicians in the treatment of MDR-TB is scarce.